Cline submits ethical application for ex-vivo testing of StemCART product on human cartilage tissue

Cline Scientific AB has submitted an ethical application to the Swedish Ethical Review Authority to gain permission to conduct testing of the StemCART project on human cartilage tissue. After approval of the permit, Cline will be able to collect samples from patients in order to carry out testing.

This human tissue will be part of a proof-of-concept ex-vivo study to test Cline’s unique allogeneic stem cell-derived chondrocytes and their ability to repair damaged cartilage. The study will be conducted together with Cline’s clinical collaborators and involve removed patient tissue that is ordinarily discarded during surgery.

 The study is planned to commence in Q4 2021 and will be an important part of the validation and further development of StemCART product and methods, a vital step to Cline’s goal of bringing StemCART to in-human clinical trials.

About StemCART
The cell-based therapy in development, StemCART, aims to repair cartilage damage with the implantation of allogeneic induced pluripotent stem cell (iPSC)-derived chondrocytes alongside a support matrix. The creation of these reparative cells is made possible by Cline’s proprietary nanotechnology that enables the directed and precise differentiation of iPSCs. This gives StemCART a big market advantage in being to have an effective allogeneic and scalable cell source for cartilage therapy. 

For more information, please contact:
Hanne Evenbratt, Director of Product Development
Email: hanne.evenbratt@clinescientific.com
Phone: +46 704 88 79 23